Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical Perspectives
Behçet’s disease is an autoinflammatory disorder characterized by relapsing and remitting vasculitis that can manifest in various forms, including gastrointestinal Behçet’s disease (GIBD). Its complications (e.g., intestinal perforation) are among the primary causes of morbidity and mortality. GIBD...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/247 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588999999356928 |
|---|---|
| author | Makoto Naganuma Mitsuhiro Takeno Aykut Ferhat Çelik Robert Moots Philippe Pinton Tadakazu Hisamatsu |
| author_facet | Makoto Naganuma Mitsuhiro Takeno Aykut Ferhat Çelik Robert Moots Philippe Pinton Tadakazu Hisamatsu |
| author_sort | Makoto Naganuma |
| collection | DOAJ |
| description | Behçet’s disease is an autoinflammatory disorder characterized by relapsing and remitting vasculitis that can manifest in various forms, including gastrointestinal Behçet’s disease (GIBD). Its complications (e.g., intestinal perforation) are among the primary causes of morbidity and mortality. GIBD pathogenesis involves the enhanced production of certain cytokines, e.g., tumor necrosis factor α and interleukin-6 (IL-6), which could serve as a target for potential therapies. This review provides an overview of GIBD, including the diagnosis and immunopathogenesis as it is currently understood, and evaluates the emerging role of the inhibition of IL-6 (classic and trans-signaling) as an alternative treatment option for patients with GIBD. Given the current paucity of data, we reflected on the potential of IL-6 inhibitors such as tocilizumab and olamkicept based on immunopathogenic considerations and available clinical data in patients with inflammatory bowel disease (IBD), in whom clinical response or remission was induced. The selective inhibition of IL-6 trans-signaling may bring new impetus to the development of this drug class, particularly regarding safety. Still, the benefits of IL-6 inhibitors for patients with GIBD need to be evaluated in appropriate proof-of-concept studies. The clinical outcomes of IL-6 inhibitors in IBD are promising and may suggest their potential relevance in GIBD. |
| format | Article |
| id | doaj-art-ad4f3f18a8974cffa99717bdf426bead |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-ad4f3f18a8974cffa99717bdf426bead2025-01-24T13:24:32ZengMDPI AGBiomedicines2227-90592025-01-0113124710.3390/biomedicines13010247Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical PerspectivesMakoto Naganuma0Mitsuhiro Takeno1Aykut Ferhat Çelik2Robert Moots3Philippe Pinton4Tadakazu Hisamatsu5Third Department of Internal Medicine, Kansai Medical University, Hirakata 573-1191, JapanDepartment of Allergy and Rheumatology, Nippon Medical School Musashi Kosugi Hospital, Kawasaki 211-8533, JapanCerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Fatih, Istanbul 34320, TürkiyeFaculty of Heath Social Care and Medicine, Edge Hill University, Ormskirk, Lancashire L39 4QP, UKClinical and Translational Sciences, Ferring Pharmaceuticals, 2770 Kastrup, DenmarkDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo 181-0004, JapanBehçet’s disease is an autoinflammatory disorder characterized by relapsing and remitting vasculitis that can manifest in various forms, including gastrointestinal Behçet’s disease (GIBD). Its complications (e.g., intestinal perforation) are among the primary causes of morbidity and mortality. GIBD pathogenesis involves the enhanced production of certain cytokines, e.g., tumor necrosis factor α and interleukin-6 (IL-6), which could serve as a target for potential therapies. This review provides an overview of GIBD, including the diagnosis and immunopathogenesis as it is currently understood, and evaluates the emerging role of the inhibition of IL-6 (classic and trans-signaling) as an alternative treatment option for patients with GIBD. Given the current paucity of data, we reflected on the potential of IL-6 inhibitors such as tocilizumab and olamkicept based on immunopathogenic considerations and available clinical data in patients with inflammatory bowel disease (IBD), in whom clinical response or remission was induced. The selective inhibition of IL-6 trans-signaling may bring new impetus to the development of this drug class, particularly regarding safety. Still, the benefits of IL-6 inhibitors for patients with GIBD need to be evaluated in appropriate proof-of-concept studies. The clinical outcomes of IL-6 inhibitors in IBD are promising and may suggest their potential relevance in GIBD.https://www.mdpi.com/2227-9059/13/1/247Behçet’s diseasebiologicsinflammatory bowel diseaseinterleukin-6olamkiceptsignaling pathways |
| spellingShingle | Makoto Naganuma Mitsuhiro Takeno Aykut Ferhat Çelik Robert Moots Philippe Pinton Tadakazu Hisamatsu Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical Perspectives Biomedicines Behçet’s disease biologics inflammatory bowel disease interleukin-6 olamkicept signaling pathways |
| title | Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical Perspectives |
| title_full | Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical Perspectives |
| title_fullStr | Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical Perspectives |
| title_full_unstemmed | Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical Perspectives |
| title_short | Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet’s Disease from Immunological and Clinical Perspectives |
| title_sort | assessment of il 6 pathway inhibition in gastrointestinal behcet s disease from immunological and clinical perspectives |
| topic | Behçet’s disease biologics inflammatory bowel disease interleukin-6 olamkicept signaling pathways |
| url | https://www.mdpi.com/2227-9059/13/1/247 |
| work_keys_str_mv | AT makotonaganuma assessmentofil6pathwayinhibitioningastrointestinalbehcetsdiseasefromimmunologicalandclinicalperspectives AT mitsuhirotakeno assessmentofil6pathwayinhibitioningastrointestinalbehcetsdiseasefromimmunologicalandclinicalperspectives AT aykutferhatcelik assessmentofil6pathwayinhibitioningastrointestinalbehcetsdiseasefromimmunologicalandclinicalperspectives AT robertmoots assessmentofil6pathwayinhibitioningastrointestinalbehcetsdiseasefromimmunologicalandclinicalperspectives AT philippepinton assessmentofil6pathwayinhibitioningastrointestinalbehcetsdiseasefromimmunologicalandclinicalperspectives AT tadakazuhisamatsu assessmentofil6pathwayinhibitioningastrointestinalbehcetsdiseasefromimmunologicalandclinicalperspectives |